Janos Roszik, PhD, MBA

Peer-Reviewed Articles

1. Nelson BE, Roszik J, Ahmed J, Barretto CMN, Nardo M, Campbell E, Johnson AM, Piha-Paul SA, Oliva ICG, Weathers SP, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer 23(1):64, 2024. e-Pub 2024. PMID: 38532456.
2. Singh S, Xiao Z, Bavisi K,Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, Singh M. Correction: IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol 212(3):500, 2024. PMID: 38088809.
3. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EEI, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun 4(2):378-387, 2024. PMID: 38126764.
4. Goldberg J, Qiao N, Guerriero JL, Gross B, Meneksedag Y, Lu YF, Philips AV, Rahman T, Meric-Bernstam F, Roszik J, Chen K, Jeselsohn R, Tolaney SM, Peoples GE, Alatrash G, Mittendorf EA. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer. Cancer Res Commun 4(2):496-504, 2024. PMID: 38335301.
5. Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S, Ali MM, Khan FS, Prabhu VV, Lorenzi P, Burton E, Morey RR, Lazcano R, Davies MA, Patel SP, Grimm EA. Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. bioRxiv, 2024. e-Pub 2024. PMID: 38293232.
6. Zhu Y, Zhang D, Shukla P, Jung YH, Malgulwar PB, Chagani S, Colic M, Benjamin S, Copland JA, Tan L, Lorenzi PL, Javle M, Huse JT, Roszik J, Hart T, Kwong LN. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight 9(2), 2024. e-Pub 2024. PMID: 38060314.
7. Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis VO, Roszik J, Livingston JA, Wang WL, Shaw KR, Ratan R, Zarzour MA, Bird J, Raza S, Akdemir KC, Rodon Ahnert J, Subbiah V, Patel S, Conley AP. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res 29(23):4844-4852, 2023. PMID: 37747813.
8. Ghosh S, Fan F, Powell RT, Roszik J, Park YS, Stephan C, Sebastian M, Tan L, Sorokin AV, Lorenzi PL, Kopetz S, Ellis LM, Bhattacharya R. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer. Mol Cancer Ther 22(8):962-975, 2023. PMID: 37310170.
9. Chen CH, Chin RL, Hartley GP, Lea ST, Engel BJ, Hsieh CE, Prasad R, Roszik J, Shingu T, Lizee GA, Heimberger AB, Millward SW, Hu J, Hong DS, Curran MA. Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. Neuro Oncol 25(8):1415-1427, 2023. PMID: 36705543.
10. Fukuda Y, Kim SH, Bustos MA, Cho SN, Roszik J, Burks JK, Kim H, Hoon DSB, Grimm EA, Ekmekcioglu S. Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Res Commun 3(7):1397-1408, 2023. e-Pub 2023. PMID: 37529399.
11. Sonnemann HM, Pazdrak B, Antunes DA, Roszik J, Lizée G. Vestigial-like 1 (VGLL1): An ancient co-transcriptional activator linking wing, placenta, and tumor development. Biochim Biophys Acta Rev Cancer 1878(3):188892, 2023. e-Pub 2023. PMID: 37004960.
12. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. PMID: 37058010.
13. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. e-Pub 2023. PMID: 37072571.
14. Nelson BE*, Roszik J*, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
15. Fan F, Ghosh S, Powell R, Roszik J, Park Y, Sobieski M, Sorokin A, Stephan C, Kopetz S, Ellis LM, Bhattacharya R. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PLoS One 18(3):e0281063, 2023. e-Pub 2023. PMID: 36952536.
16. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. PMID: 36288393.
17. Chattopadhyay C, Bhattacharya R, Roszik J, Khan FS, Wells GA, Villanueva H, Qin Y, Bhattacharya R, Patel SP, Grimm EA. Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth. Cancers (Basel) 14(24), 2022. e-Pub 2022. PMID: 36551732.
18. Chen Z, Zheng L, Chen Y, Liu X, Kawakami M, Mustachio LM, Roszik J, Ferry-Galow KV, Parchment RE, Liu X, Andresson T, Duncan G, Kurie JM, Rodriguez-Canales J, Liu X, Dmitrovsky E. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis. Cancer Biol Ther 23(1):265-280, 2022. PMID: 35387560.
19. Roszik J, Lee JJ, Wu YH, Liu X, Kawakami M, Kurie JM, Belouali A, Boca SM, Gupta S, Beckman RA, Madhavan S, Dmitrovsky E. Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival. Cancer Res Commun 2(7):590-601, 2022. e-Pub 2022. PMID: 35832288.
20. Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol 6:e2100547, 2022. PMID: 35862868.
21. Jackson KR, Antunes DA, Talukder AH, Maleki AR, Amagai K, Salmon A, Katailiha AS, Chiu Y, Fasoulis R, Rigo MM, Abella JR, Melendez BD, Li F, Sun Y, Sonnemann HM, Belousov V, Frenkel F, Justesen S, Makaju A, Liu Y, Horn D, Lopez-Ferrer D, Huhmer AF, Hwu P, Roszik J, Hawke D, Kavraki LE, Lizée G. Charge-based interactions through peptide position 4 drive diversity of antigen presentation by human leukocyte antigen class I molecules. PNAS Nexus 1(3):pgac124, 2022. e-Pub 2022. PMID: 36003074.
22. Adashek JJ, Menta AK, Reddy NK, Desai AP, Roszik J, Subbiah V. Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Mol Cancer Ther 21(6):871-878, 2022. PMID: 35413124.
23. Brashears CB, Prudner BC, Rathore R, Caldwell KE, Dehner CA, Buchanan JL, Lange SES, Poulin N, Sehn JK, Roszik J, Spitzer D, Jones KB, O'Keefe RJ, Nielsen TO, Taylor EB, Held JM, Hawkins W, Van Tine BA. Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT3102. Clin Cancer Res. e-Pub 2022. PMID: 35421237.
24. Fan F, Roszik J, Xia L, Ghosh S, Wang R, Ye X, Hawke D, Ellis LM, Bhattacharya R. Cytospin-A Regulates Colorectal Cancer Cell Division and Migration by Modulating Stability of Microtubules and Actin Filaments. Cancers (Basel) 14(8), 2022. e-Pub 2022. PMID: 35454887.
25. Fukuda Y, Bustos MA, Cho SN, Roszik J, Ryu S, Lopez VM, Burks JK, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu S. Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis 13(2):117, 2022. e-Pub 2022. PMID: 35121729.
26. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
27. Banerjee P, Xiao GY, Tan X, Zheng VJ, Shi L, Rabassedas MNB, Guo HF, Liu X, Yu J, Diao L, Wang J, Russell WK, Roszik J, Creighton CJ, Kurie JM. The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. Nat Commun 12(1):6354, 2021. e-Pub 2021. PMID: 34732702.
28. Adashek JJ, Desai AP, Andreev-Drakhlin AY, Roszik J, Cote GJ, Subbiah V. Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers. Mol Cancer Ther 20(10):1769-1776, 2021. e-Pub 2021. PMID: 34493590.
29. Pestana RC, Roszik J, Groisberg R, Sen S, Van Tine BA, Conley AP, Subbiah V. Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Curr Probl Cancer 45(5):100794, 2021. e-Pub 2021. PMID: 34656365.
30. Kairemo K, Roszik J, Anderson P, Ravizzini G, Rao A, Macapinlac HA, Subbiah V. 18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. Curr Probl Cancer 45(5):100797, 2021. e-Pub 2021. PMID: 34706830.
31. Roszik J, Mustachio LM, Livingston JA, Groisberg R, Carmagnani Pestana R, Subbiah V, Conley AP. Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. Cancers (Basel) 13(20), 2021. e-Pub 2021. PMID: 34680396.
32. Patel SP, Petroni GR, Roszik J, Olson WC, Wages NA, Chianese-Bullock KA, Smolkin M, Varhegyi N, Gaughan E, Smith KT, Haden K, Hall EH, Gnjatic S, Hwu P, Slingluff CL. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. J Immunother Cancer 9(8), 2021. PMID: 34413169.
33. Zhu L, Hobbs B, Roszik J, Holla V, Hong DS. Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors. Invest New Drugs. e-Pub 2021. PMID: 34341905.
34. Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: 33745946.
35. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. e-Pub 2021. PMID: 34362693.
36. Ma Y, Brown PM, Lin DD, Ma J, Feng D, Belyaeva OV, Podszun MC, Roszik J, Allen JN, Umarova R, Kleiner DE, Kedishvili NY, Gavrilova O, Gao B, Rotman Y. Hsd17b13 Deficiency Does not Protect Mice From Obesogenic Diet Injury. Hepatology 73(5):1701-1716, 2021. e-Pub 2021. PMID: 32779242.
37. Miskei M, Horváth A, Viola L, Varga L, Nagy É, Feró O, Karányi Z, Roszik J, Miskey C, Ivics Z, Székvölgyi L. Genome-wide mapping of binding sites of the transposase-derived SETMAR protein in the human genome. Comput Struct Biotechnol J 19:4032-4041, 2021. e-Pub 2021. PMID: 34377368.
38. Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei CH, Roszik J, Kittai AS, Danilov AV, Zhang X, Fang B, Wang J, Heymach JV, Tyutyunyk-Massey L, Freemantle SJ, Kurie JM, Liu X, Dmitrovsky E. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis and Metastasis in Aneuploid Cancers. Mol Cancer Ther. e-Pub 2020. PMID: 33277443.
39. Ogata D, Roszik J, Oba J, Kim SH, Bassett RL, Haydu LE, Tanese K, Grimm EA, Ekmekcioglu S. The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33327409.
40. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res. e-Pub 2020. PMID: 33323389.
41. Varghese S, Pramanik S, Williams LJ, Hodges HR, Hudgens CW, Fischer GM, Luo CK, Knighton B, Tan L, Lorenzi PL, MacKinnon AL, McQuade JL, Hailemichael Y, Roszik J, Peng W, Vashisht Gopal YN. The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies. Mol Cancer Ther. e-Pub 2020. PMID: 33361272.
42. Liu X, Lu Y, Chen Z, Liu X, Hu W, Zheng L, Chen Y, Kurie JM, Shi M, Mustachio LM, Andresson T, Fox S, Roszik J, Kawakami M, Freemantle S, Dmitrovsky E. The Ubiquitin Specific Protease USP18 Promotes Lipolysis, Fatty Acid Oxidation and Lung Cancer Growth. Mol Cancer Res. e-Pub 2020. PMID: 33380466.
43. Qin Y, Bollin K, de Macedo MP, Carapeto F, Kim KB, Roszik J, Wani KM, Reuben A, Reddy ST, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Lazar AJ, Hwu P, Patel SP. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. J Immunother Cancer 8(2), 2020. PMID: 33203661.
44. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6), 2020. PMID: 33229506.
45. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5), 2020. PMID: 33097651.
46. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun 11(1):5332, 2020. e-Pub 2020. PMID: 33087697.
47. Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, Xu C, Forget MA, Haymaker C, Khalili JS, Satani N, Muller F, Cooper LJN, Overwijk WW, Amaria RN, Bernatchez C, Heffernan TP, Peng W, Roszik J, Hwu P. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunol Immunother, 2020. e-Pub 2020. PMID: 33123754.
48. Sen S, Tanaka R, Khatua S, Zaky W, Janku F, Penas-Prado M, Weathers SP, Behrang A,Roszik J, Subbiah V. Dual inhibition of BRAF and mTOR in BRAF V600E -mutant pediatric, adolescent, and young adult brain tumors. Cold Spring Harb Mol Case Stud 6(4), 2020. e-Pub 2020. PMID: 32843426.
49. Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, Gonzalez-Lepera C, Liu H, Macapinlac H, Meric-Bernstam F, Hong DS, Pant S, Le D, Santos E, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S, Ravizzini G. Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res. e-Pub 2020. PMID: 32816889.
50. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, morphoproteomics, and treatment patterns of alveolar soft part sarcoma patients and response to multiple experimental therapies. Mol Cancer Ther. e-Pub 2020. PMID: 32127467.
51. Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discov. e-Pub 2020. PMID: 32029534.
52. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
53. Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AK. Mechanisms of nuclear content loading to exosomes. Sci Adv 5(11):eaax8849, 2019. e-Pub 2019. PMID: 31799396.
54. Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SE. Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. Invest Ophthalmol Vis Sci 60(13):4187-4195, 2019. PMID: 31596927.
55. Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN, Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni D, Markel G, Leibowitz-Amit R. TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma. Cancer Immunol Immunother. e-Pub 2019. PMID: 31501955.
56. Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri A. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunol Immunother. e-Pub 2019. PMID: 31515669.
57. Vashisht Gopal YN, Gammon ST, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens CW, Fischer GM, Deng W, Reuben A, Peng W, Wang J, Di Francesco ME, Marszalek JR, McQuade JL, Tetzlaff MT, Piwnica-Worms D, DeBerardinis RJ, Davies MA. A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor-resistance in melanoma. Clin Cancer Res. e-Pub 2019. PMID: 31439581.
58. Roszik J, Khan A, Conley AP, Livingston JA, Groisberg R, Ravi V, Carmagnani Pestana R, Sen S, Subbiah V. Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers (Basel) 11(9), 2019. e-Pub 2019. PMID: 31480474.
59. Boros-Oláh B, Dobos N, Hornyák L, Szabó Z, Karányi Z, Halmos G, Roszik J, Székvölgyi L. Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy. DNA Repair (Amst):102642. e-Pub 2019. PMID: 31300387.
60. Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behren C, Mino B, Solis LM, Silvester J, Thu KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Threonine Tyrosine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. Mol Cancer Ther. e-Pub 2019. PMID: 31358662.
61. Anand K, Roszik J, Gombos D, Upshaw J, Sarli V, Meas S, Lucci A, Hall C, Patel S. Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. Cancers (Basel) 11(6), 2019. e-Pub 2019. PMID: 31226786.
62. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31096717.
63. Grinshpun A, Zarbiv Y, Roszik J, Subbiah V, Hubert A. Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. Case Rep Oncol 12(1):7-13, 2019. e-Pub 2019. PMID: 30792639.
64. Mustachio LM,Roszik J, Farria AT, Guerra K, Dent SY. Repression of GCN5 expression or activity attenuates c-MYC expression in non-small cell lung cancer. Am J Cancer Res 9(8):1830-1845, 2019. e-Pub 2019. PMID: 31497362.
65. Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform 2:1-12, 2018. PMID: 30652536.
66. Mahendra A, Yang X, Abnouf S, Adolacion JRT, Park D, Soomro S, Roszik J, Coarfa C, Romain G, Wanzeck K, Louis Bridges S, Aggarwal A, Qiu P, Agarwal SK, Mohan C, Varadarajan N. Beyond autoantibodies: Biological roles of human autoreactive B cells in rheumatoid arthritis revealed by RNA-sequencing. Arthritis Rheumatol. e-Pub 2018. PMID: 30407753.
67. Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Yang SM, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4. Mol Cancer Ther. e-Pub 2018. PMID: 30420565.
68. Cardoso C, Serafim RB, Kawakami A, Pereira CG, Roszik J, Valente V, Vazquez VL, Fisher DE, Espreafico EM. The lncRNA RMEL3 protects immortalized cells from serum withdrawal-induced growth arrest and promotes melanoma cell proliferation and tumor growth. Pigment Cell Melanoma Res. e-Pub 2018. PMID: 30457212.
69. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Syst 7(4):422-437.e7, 2018. e-Pub 2018. PMID: 30268436.
70. Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SR. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol(4):1-6, 2018. e-Pub 2017. PMID: 30241159.
71. Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O, Talukder A, Forget MA, Haymaker C, Bernatchez C, Han L, Tsang YH, Kong K, Xu X, Scott KL, Singh-Jasuja H, Lizee G, Liang H, Weinschenk T, Mills GB, Hwu P. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun 9(1):3919, 2018. e-Pub 2018. PMID: 30254248.
72. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets TV, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth C, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn CS, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MKK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res. e-Pub 2018. PMID: 29848573.
73. Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest 128(4):1338-1354, 2018. e-Pub 2018. PMID: 29480817.
74. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33(4):690-705.e9, 2018. e-Pub 2018. PMID: 29622464.
75. Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. e-Pub 2018. PMID: 29654067.
76. Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol. e-Pub 2018. PMID: 29710228.
77. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan TP, Amaria RN, Korkut A, Peng W, Roszik J, Lizee G, Woodman SE, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res. e-Pub 2018. PMID: 29496759.
78. Sepesi B, Nelson DB, Mitchell KG, Gibbons DL, Heymach JV, Vaporciyan AA, Swisher SG, Roszik J. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. Ann Thorac Surg. e-Pub 2018. PMID: 29510096.
79. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. e-Pub 2018. PMID: 29628419.
80. Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proc Natl Acad Sci U S A 115(8):1913-1918, 2018. e-Pub 2018. PMID: 29434041.
81. Mustachio LM, Lu Y, Kawakami M, Roszik J, Freemantle SJ, Liu X, Dmitrovsky E. Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target. Cancer Res. e-Pub 2018. PMID: 29343520.
82. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 30148248.
83. Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol 9:2102, 2018. e-Pub 2018. PMID: 30283446.
84. Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 31058252.
85. Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, Jenoe P, Heim MH, Riezman I, Riezman H, Hall MN. mTORC2 Promotes Tumorigenesis via Lipid Synthesis. Cancer Cell 32(6):807-823.e12, 2017. PMID: 29232555.
86. McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE, Hwu P. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. J Natl Cancer Inst. e-Pub 2017. PMID: 29267866.
87. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
88. Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca, Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171(4):950-965.e28, 2017. PMID: 29100075.
89. Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun 8(1):451, 2017. e-Pub 2017. PMID: 28878208.
90. Mizrahi A, Barzilai A, Gur-Wahnon D, Ben-Dov IZ, Glassberg S, Meningher T, Elharar E, Masalha M, Jacob-Hirsch J, Tabibian-Keissar H, Barshack I, Roszik J, Leibowitz-Amit R, Sidi Y, Avni D. Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes. Oncogene. e-Pub 2017. PMID: 28925390.
91. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell 32(2):204-220.e15, 2017. PMID: 28810145.
92. Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C. Multifaceted Role of BTLA in the Control of CD8(+) T-cell Fate after Antigen Encounter. Clin Cancer Res. e-Pub 2017. PMID: 28754817.
93. Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst 109(6), 2017. PMID: 28376145.
94. Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM. 4-1BB-enhanced expansion of CD8+ TIL from triple-negative breast cancer unveils mutation-specific CD8+ T cells. Cancer Immunol Res 5(6):439-445, 2017. e-Pub 2017. PMID: 28473315.
95. Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11, 2017. e-Pub 2017. PMID: 28630682.
96. Park J, Talukder AH, Lim S, Kim K, Pan K, Melendez B, Bradley SD, Jackson K, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM,Roszik J, Lizee G, Yee C. SLC45A2: A melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunol Res. e-Pub 2017. PMID: 28630054.
97. Hetey S, Boros-Oláh B, Kuik-Rózsa T, Li Q, Karányi Z, Szabó Z, Roszik J, Szalóki N, Vámosi G, Tóth K, Székvölgyi L. Biophysical characterization of histone H3.3 K27 M point mutation. Biochem Biophys Res Commun. e-Pub 2017. PMID: 28647357.
98. Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, Dmitrovsky E, Liu X. The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer. J Thorac Oncol. e-Pub 2017. PMID: 28552766.
99. Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA. Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma. Clin Cancer Res. e-Pub 2017. PMID: 28377484.
100. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. PMID: 28251903.
101. Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res. e-Pub 2017. PMID: 28254787.
102. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 18(11):2780-2794, 2017. PMID: 28297679.
103. Mustachio LM, Lu Y, Tafe LJ, Memoli V, Rodriguez-Canales J, Mino B, Villalobos PA, Wistuba I, Katayama H, Hanash SM, Roszik J, Kawakami M, Cho KJ, Hancock JF, Chinyengetere F, Hu S, Liu X, Freemantle SJ, Dmitrovsky E. Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer. Mol Cancer Res. e-Pub 2017. PMID: 28242811.
104. Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 31(1):234-237, 2017. e-Pub 2016. PMID: 27573556.
105. Qin Y, Conley AP, Grimm EA, Roszik J. A tool for discovering drug sensitivity and gene expression associations in cancer cells. PLoS One 12(4):e0176763, 2017. e-Pub 2017. PMID: 28453553.
106. Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol 8:689, 2017. e-Pub 2017. PMID: 28670312.
107. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
108. Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Front Immunol 8:1975, 2017. e-Pub 2018. PMID: 29422892.
109. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. Cancer. e-Pub 2016. PMID: 27911979.
110. Mustachio LM, Kawakami M, Lu Y, Rodriguez-Canales J, Mino B, Behrens C, Wistuba I, Bota-Rabassedas N, Yu J, Lee JJ, Roszik J, Zheng L, Liu X, Freemantle SJ, Dmitrovsky E. The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget. e-Pub 2016. PMID: 27980214.
111. Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola FM, Hwu P, Grimm EA, Radvanyi LG. IL-2 variant circumvents ICOS+ regulatory T cell expansion and promotes NK cell activation. Cancer Immunol Res. e-Pub 2016. PMID: 27697858.
112. Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep 6:35848, 2016. e-Pub 2016. PMID: 27762323.
113. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14(1):168, 2016. e-Pub 2016. PMID: 27776519.
114. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T,Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. e-Pub 2016. PMID: 27667683.
115. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol 2(8):1056-64, 2016. e-Pub 2016. PMID: 27124486.
116. Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko JM, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell Melanoma Res 29(4):470-3, 2016. e-Pub 2016. PMID: 27089234.
117. Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Mol Cancer Ther. e-Pub 2016. PMID: 27458138.
118. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res 22(12):3016-24, 2016. e-Pub 2016. PMID: 26783288.
119. Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res 29(3):297-308, 2016. e-Pub 2016. PMID: 26801201.
120. Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A 113(21):5999-6004, 2016. e-Pub 2016. PMID: 27162338.
121. Goedert L*, Pereira CG*, Roszik J*, Plaça JR, Cardoso C, Chen G, Deng W, Yennu-Nanda VG, Silva WA, Davies MA, Espreafico EM. RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. Oncotarget. e-Pub 2016. PMID: 27167340.
122. Najjar AM, Manuri PR, Olivares S, Flores L, Mi T, Huls H, Shpall EJ, Champlin RE, Turkman N, Paolillo V, Roszik J, Rabinovich B, Lee DA, Alauddin M, Gelovani J, Cooper LJ. Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. Mol Imaging Biol. e-Pub 2016. PMID: 27246312.
123. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2015. PMID: 26645196.
124. Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22(2):374-82, 2016. e-Pub 2015. PMID: 26307133.
125. Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep 6:19649, 2016. e-Pub 2016. PMID: 26787600.
126. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HM, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LW, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang H. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell 28(4):515-28, 2015. e-Pub 2015. PMID: 26439496.
127. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res 75(17):3554-67, 2015. e-Pub 2015. PMID: 26206558.
128. Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681-96, 2015. PMID: 26091043.
129. Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res 28(3):357-9, 2015. e-Pub 2015. PMID: 25515650.
130. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2014. PMID: 25148578.
131. Govers C, Sebestyén Z, Roszik J, van Brakel M, Berrevoets C, Szöor Á, Panoutsopoulou K, Broertjes M, Van T, Vereb G, Szöllosi J, Debets R. TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity. J Immunol 193(10):5315-26, 2014. e-Pub 2014. PMID: 25320284.
132. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111(29):10660-5, 2014. e-Pub 2014. PMID: 25002471.
133. Roszik J, Woodman SE. HotSpotter: efficient visualization of driver mutations. BMC Genomics 15:1044, 2014. e-Pub 2014. PMID: 25435088.
134. Liadi I, Roszik J, Romain G, Cooper LJ, Varadarajan N. Quantitative high-throughput single-cell cytotoxicity assay for T cells. J Vis Exp(72):e50058, 2013. e-Pub 2013. PMID: 23407457.
135. Beyer D, Tándor I, Kónya Z, Bátori R, Roszik J, Vereb G, Erdodi F, Vasas G, M-Hamvas M, Jambrovics K, Máthé C. Microcystin-LR, a protein phosphatase inhibitor, induces alterations in mitotic chromatin and microtubule organization leading to the formation of micronuclei in Vicia faba. Ann Bot 110(4):797-808, 2012. e-Pub 2012. PMID: 22819947.
136. Váradi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, Galmarini CM, Szöllosi J, Nagy P. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur J Pharmacol 667(1-3):91-9, 2011. e-Pub 2011. PMID: 21658382.
137. Roszik J, Sebestyén Z, Govers C, Guri Y, Szöor A, Pályi-Krekk Z, Vereb G, Nagy P, Szöllosi J, Debets R. T-cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR:ζ, a candidate transgene for TCR gene therapy. Eur J Immunol 41(5):1288-97, 2011. e-Pub 2011. PMID: 21469084.
138. Roszik J, Lisboa D, Szöllosi J, Vereb G. Evaluation of intensity-based ratiometric FRET in image cytometry--approaches and a software solution. Cytometry A 75(9):761-7, 2009. PMID: 19591240.
139. Beyer D, Surányi G, Vasas G, Roszik J, Erdodi F, M-Hamvas M, Bácsi I, Bátori R, Serfozo Z, Szigeti ZM, Vereb G, Demeter Z, Gonda S, Máthé C. Cylindrospermopsin induces alterations of root histology and microtubule organization in common reed (Phragmites australis) plantlets cultured in vitro. Toxicon 54(4):440-9, 2009. e-Pub 2009. PMID: 19464311.
140. Roszik J, Szöllosi J, Vereb G. AccPbFRET: an ImageJ plugin for semi-automatic, fully corrected analysis of acceptor photobleaching FRET images. BMC Bioinformatics 9:346, 2008. e-Pub 2008. PMID: 18713453.
141. Roszik J, Sztrik J, Virtamo J. Performance analysis of finite-source retrial queues operating in random environments. International Journal of Operational Research 2:254-268, 2007.
142. Almasi B, Roszik J, Sztrik J. Homogeneous finite-source retrial queues with server subject to breakdowns and repairs. Mathematical and Computer Modelling 42:673-682, 2005.

Invited Articles

1. Mustachio LM, Roszik J. Single-Cell Sequencing: Current Applications in Precision Onco-Genomics and Cancer Therapeutics. Cancers (Basel) 14(3), 2022. e-Pub 2022. PMID: 35158925.
2. Gupta RG, Li F, Roszik J, Lizée G. Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches. Cancer Discov 11(5):1024-1039, 2021. e-Pub 2021. PMID: 33722796.
3. Mustachio LM, Chelariu-Raicu A, Szekvolgyi L, Roszik J. Targeting KRAS in Cancer: Promising Therapeutic Strategies. Cancers (Basel) 13(6), 2021. e-Pub 2021. PMID: 33801965.
4. Mustachio LM, Roszik J. Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 13(11), 2020. e-Pub 2020. PMID: 33182254.
5. Adashek JJ, Leonard A, Roszik J, Menta AK, Genovese G, Subbiah V, Msaouel P. Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers (Basel) 12(3), 2020. e-Pub 2020. PMID: 32197306.
6. Mustachio LM, Roszik J, Farria A, Dent SYR. Targeting the SAGA and ATAC transcriptional coactivator complexes in MYC-driven cancers. Cancer Res. e-Pub 2020. PMID: 32094302.
7. Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E. Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. Proc Natl Acad Sci U S A 115(46):E10810-E10811, 2018. e-Pub 2018. PMID: 30377273.
8. Roszik J, Subbiah V. Mining Public Databases for Precision Oncology. Trends Cancer 4(7):463-465, 2018. e-Pub 2018. PMID: 29937043.
9. El Beaino M, Roszik J, Livingston JA, Wang WL, Lazar AJ, Amini B, Subbiah V, Lewis V, Conley AP. Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Curr Oncol Rep 20(5):37, 2018. e-Pub 2018. PMID: 29582189.
10. Kim SH, Roszik J, Grimm EA, Ekmekcioglu S. Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy. Front Oncol 8:67, 2018. e-Pub 2018. PMID: 29616189.
11. Guri Y, Nordmann TM, Roszik J. mTOR at the Transmitting and Receiving Ends in Tumor Immunity. Front Immunol 9:578, 2018. e-Pub 2018. PMID: 29662490.
12. Li Y, Patel SP, Roszik J, Qin Y. Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy. Front Immunol 9:1591, 2018. e-Pub 2018. PMID: 30061885.
13. Fillér C, Hornyák L, Roszik J. Commentary: Nuclear dynamics of the Set1C subunit Spp1 prepares meiotic recombination sites for break formation. Front Genet 9:496, 2018. e-Pub 2018. PMID: 30405701.
14. Groisberg R, Roszik J, Conley A, Patel SR, Subbiah V. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep 19(12):78, 2017. e-Pub 2017. PMID: 29030741.
15. Roszik J, Fenyofalvi G, Halász L, Karányi Z, Székvölgyi L. In Silico Restriction Enzyme Digests to Minimize Mapping Bias in Genomic Sequencing. Mol Ther Methods Clin Dev 6:66-67, 2017. e-Pub 2017. PMID: 28695155.
16. Marcus R, Maitra A, Roszik J. Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. J Pathol. e-Pub 2017. PMID: 28816351.
17. Lam M*, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG. The potential role of platelets in the consensus molecular subtypes of colorectal cancer. Cancer Metastasis Rev. e-Pub 2017. PMID: 28681242.
18. Subbiah V, Roszik J. Towards Precision Oncology in RET-aberrant Cancers. Cell Cycle:0. e-Pub 2017. PMID: 28318386.
19. Ekmekcioglu S, Grimm EA, Roszik J. Targeting iNOS to increase efficacy of immunotherapies. Hum Vaccin Immunother. e-Pub 2017. PMID: 28121247.
20. Roszik J, Tóth G, Szöllosi J, Vereb G. Validating pharmacological disruption of protein-protein interactions by acceptor photobleaching FRET imaging. Methods Mol Biol 986:165-78, 2013. PMID: 23436412.

Other Articles

1. Roszik J, Sztrik J Performance analysis of finite-source retrial queues with nonreliable heterogenous servers. Journal of Mathematical Sciences 146:6033-6038, 2007.
2. Sztrik J, Almasi B, Roszik J Heterogeneous finite-source retrial queues with server subject to breakdowns and repairs. Journal of Mathematical Sciences 132:677-685, 2006.
3. Roszik J, Sztrik J, Kim CS Retrial queues in the performance modeling of cellular mobile networks using MOSEL. International Journal of Simulation 6:38-47, 2005.
4. Hyytia E, Lassila P, Penttinen A, Roszik J Traffic load in a wireless multihop network. PE-WASUN'05 - Proceedings of the Second ACM International Workshop on Performance Evaluation of Wireless Ad Hoc, Sensor, and Ubiquitous Networks:9-17, 2005.

Editorials

1. Mustachio LM, Roszik J. Opportunities for Single-Cell Sequencing Technologies and Data Science. Cancers (Basel) 12(11), 2020. PMID: 33227959.
2. Roszik J, Tanese K, Ekmekcioglu S. Editorial: Targeting Metabolism in Cancer Immunotherapy. Front Immunol 9:2029, 2018. PMID: 30254633.
3. Roszik J, Rabinovich B, Cooper LJ. Imaging of T cells expressing chimeric antigen receptors. Immunotherapy 3(12):1411-4, 2011. PMID: 22091674.

Abstracts

1. Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res 25(5):1650-1663, 2019. e-Pub 2018. PMID: 30538110.

Book Chapters

1. Sun-Hee Kim, Dai Ogata, Jason Roszik, Elizabeth A. Grimm, Suhendan Ekmekcioglu. Arginine Metabolism Regulates Nitric Oxide Production in Melanoma Tumor Microenvironment to Provide Survival Advantage to Tumor Cells. In: Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders. Academic Press Inc (Elsevier), 2019.
2. Jason Roszik, Vivek Subbiah, Anthony Conley. Sarcoma (Gastrointestinal Stromal Tumors, GIST). In: Handbook of Targeted Cancer Therapy and Immunotherapy. Wolters Kluwer, 2018.